<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677712</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-401</org_study_id>
    <nct_id>NCT04677712</nct_id>
  </id_info>
  <brief_title>Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite</brief_title>
  <acronym>MOBI</acronym>
  <official_title>A Collaborative Research, Open-Label Study to Assess Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite in Adult Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCSD Dermatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Wall Center for Plastic Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mathew Avram, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laser &amp; Skin Surgery Medical Group, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Investigate MD, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brian Biesman, MD, PLLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Plastic Surgical Associates of Fort Collins, P.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QWO™ (CCH-aaes) is indicated for the treatment of moderate to severe cellulite in the&#xD;
      buttocks of adult women. QWO™ (CCH-aaes)-related post-injection bruising was the most common&#xD;
      adverse reaction; generally, resolving within 21 days. Since bruising may be bothersome to&#xD;
      patients, this study will investigate treatments that may mitigate bruising after QWO™&#xD;
      (CCH-aaes) treatment of cellulite in the buttocks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Actual">September 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 26, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Assessment of Bruising Severity Scale</measure>
    <time_frame>Day 4</time_frame>
    <description>The proportion of participants by buttock at each level of bruising on the Investigator Assessment of Bruising Severity Scale, after QWO™ (CCH-aaes) injection. This 5-level scale ranges from 0 to 4, with &quot;0&quot; indicating no bruising or almost none, and &quot;4&quot; indicating very severe bruising.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-Bruising Improvement Scale</measure>
    <time_frame>Day 2, 4, 7, 14, and 22</time_frame>
    <description>The proportion of participants with an improvement of bruising on the mitigation treated buttock on the Investigator-Bruising Improvement Scale (I-BIS), a 3-point Likert scale, with a score on the higher end of the range indicating improvement with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Bruising Severity Scale</measure>
    <time_frame>Day 1, 2, 4, 7, 14, and 22</time_frame>
    <description>The proportion of participants by buttock at each level of bruising on the Investigator Assessment of Bruising Severity Scale, by visit. This 5-level scale ranges from 0 to 4, with 0 indicating no bruising or almost none, and 4 indicating severe bruising.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-Bruising Improvement Scale (S-BIS)</measure>
    <time_frame>Day 2, 4, 7, 14, and 22</time_frame>
    <description>The proportion of participants treated with QWO™ (CCH-aaes) with an improvement of bruising on the mitigation treated buttock on the Subject-Bruising Improvement Scale (S-BIS), a 3-point Likert scale, with a score on the higher end of the range indicating improvement of bruising with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Bother by Bruising Scale</measure>
    <time_frame>Day 4, 7, and 22</time_frame>
    <description>The proportion of participants by buttock on the Patient Bother by Bruising Scale, a 4-point scale, with a score of 1 indicating not bothered at all, and a score of 4, indicating extremely bothered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Global Aesthetic Improvement Scale (I-GAIS)</measure>
    <time_frame>Day 22, 43, and 71</time_frame>
    <description>The proportion of participants with an improved (+1 or better) score on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for either buttock. The I-GAIS is a 7-level scale ranging from +3 (very much improved) to -3 (very much worse)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy (EFP)</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Compression Garments</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Instant Cold Packs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Arnica Gel Patches (OcuMend)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: INhance Post-Injection Serum with TriHex Technology®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Pulse Dye Laser Treatment (PDL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + No Mitigation Treatment</intervention_name>
    <description>Cohort 1 will serve as a control and no mitigation treatment will be administered</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + Compression</intervention_name>
    <description>Participants will use compression garments</description>
    <arm_group_label>Cohort 2: Compression Garments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + Cold Packs</intervention_name>
    <description>Participants will use cold packs</description>
    <arm_group_label>Cohort 3: Instant Cold Packs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + Arnica gel</intervention_name>
    <description>Participants will use Arnica Gel Patches</description>
    <arm_group_label>Cohort 4: Arnica Gel Patches (OcuMend)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + INhance®</intervention_name>
    <description>Participants will use INhance®</description>
    <arm_group_label>Cohort 5: INhance Post-Injection Serum with TriHex Technology®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QWO™(CCH-aaes) + PDL</intervention_name>
    <description>Participants will be treated with PDL</description>
    <arm_group_label>Cohort 6: Pulse Dye Laser Treatment (PDL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have both buttocks with:&#xD;
&#xD;
               1. a CR-PCSS score of 3 (moderate) as reported by the Investigator, and&#xD;
&#xD;
               2. a Hexsel CSS Subsection D &quot;Grade of laxity, flaccidity, or sagging skin&quot; score of&#xD;
                  0 (absence of laxity, flaccidity, or sagging skin) or 1 (slightly draped&#xD;
                  appearance).&#xD;
&#xD;
          2. Have a body mass index between ≥18 and ≤30 kg/m^2.&#xD;
&#xD;
          3. Be willing to apply sunscreen to the treatment areas before each exposure to the sun&#xD;
             for the duration of the study (from Screening Visit through the Day 71/Early&#xD;
             Termination Visit).&#xD;
&#xD;
          4. Be judged to be in good health.&#xD;
&#xD;
          5. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has Coagulation disorder, which requires anticoagulant or antiplatelet medication&#xD;
             during the study (except for &lt; 150 mg aspirin daily), or has taken anticoagulant or&#xD;
             antiplatelet medication(s) within 14 days before injection of study treatment (except&#xD;
             for &lt; 150 mg aspirin daily).&#xD;
&#xD;
          2. Has local conditions in the areas to be treated (Thrombosis, Vascular disorder, Active&#xD;
             infection/inflammation, Active cutaneous alteration, Tattoo/mole) that restricts study&#xD;
             participation.&#xD;
&#xD;
          3. Has skin laxity or linear undulations on buttocks that can be effaced by lifting skin.&#xD;
&#xD;
          4. Requires the following concomitant medications during the study and cannot discontinue&#xD;
             these medications within the time specified before QWO (CCH-aaes) treatment.&#xD;
&#xD;
               1. Antiplatelet medication (clopidogrel [Plavix®] including aspirin at any dose&#xD;
                  within 14 days of treatment.&#xD;
&#xD;
               2. Anticoagulants, such as warfarin (Coumadin®); heparin analogues within 14 days of&#xD;
                  treatment.&#xD;
&#xD;
               3. Non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen (Motrin®,&#xD;
                  Advil®) and naproxen (Aleve®) 7 days before the study.&#xD;
&#xD;
               4. Any medications or food that have, or have been reported to have anticoagulant&#xD;
                  effects within 14 days of treatment.&#xD;
&#xD;
               5. Antibiotics, such as penicillin and cephalosporin within 48 hours of treatment.&#xD;
&#xD;
          5. Has used or intends to use any of the local&#xD;
             applications/therapies/injections/procedures that restricts study participation.&#xD;
&#xD;
          6. Is pregnant and/or is presently nursing or providing breast milk or plans to become&#xD;
             pregnant during the study.&#xD;
&#xD;
          7. Intends to initiate an intensive sport or exercise program during the study.&#xD;
&#xD;
          8. Tanning or use of tanning agents.&#xD;
&#xD;
          9. Intends to engage in strenuous activity within 48 hours after the first injection of&#xD;
             QWO (CCH-aaes).&#xD;
&#xD;
         10. Has received an investigational drug or treatment within 30 days prior to injection of&#xD;
             QWO (CCH-aaes).&#xD;
&#xD;
         11. Has a history of hypersensitivity or allergy to collagenase or any other excipient of&#xD;
             QWO (CCH-aaes).&#xD;
&#xD;
         12. Has a known systemic allergy or local sensitivity to any of the mitigation treatments&#xD;
             or including excipients (ie, arnica patches, INhance Post-injection Serum).&#xD;
&#xD;
         13. Has received any collagenase treatments at any time prior to treatment in this study&#xD;
             and/or has received EN3835 or QWO (CCH-aaes) in a previous investigational study for&#xD;
             cellulite.&#xD;
&#xD;
         14. For subjects allocated to PDL treatment Subjects will be excluded from PDL treatment&#xD;
             if they have any contraindications to PDL a. exposure to Accutane® (isotretinoin)&#xD;
             within 6 months of QWO (CCH-aaes) treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Tayi</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #7</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #6</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #5</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #8</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #4</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

